Objective: To evaluate the inhibitory activity of WX-JT on alpha glucosidase and the effects of WX-JT(a compound Chinese medicine) on indexes associated with blood glucose in type 2 diabetic KK-Ay mice. Method: ①Everted rat intestine experiment: normal adult Wistar rats were sacrificed and whole small intestine was removed and made into intestinal sac. The intestinal sac was placed inside the conical flask with stopper containing substrate with WX-JT and acarbose. After incubating at 37 ℃ for 2 h

liquid in all conical flask was collected and the glucose level was measured. ②In vivo evaluation of oral starch tolerance experiment. Forty ICR mice were randomly divided into 5 groups

the fasting blood glucose was measured after all mice were fasted for 12 h. Mice in WX-JT group and acarbose group were given starch solution after acute treatment at 45.24

90.48

180.96 mg·kg-1WX-JT and acarbose respectively

and mice in control group were given starch solution in the same volume by gavage. The blood glucose was measured respectively at 30

60

120 min after oral administration. ③All mice were divided into untreated group

acarbose group

WX-JT low (180.96 mg·kg-1) and high dose (361.92 mg·kg-1) treatment group according to FBG and weight. Ten C57 BL/6J mice were taken as normal group. Acarbose and WX-JT were given by oral administration for 9 weeks. Mice in normal group and untreated group were administered orally with sterile water in the same dosage. Fasting blood glucose was detected in every odd week and non-fasting blood glucose was detected in each even week. Oral glucose tolerance (OGTT) was detected 9 weeks later. The level of glycohemoglobin (HbA1c) was measured after all the mice were sacrificed. Result: ①The everted rat intestine experiment showed that 7-189 mg·L-1 WX-JT could inhibit the activity of alpha glucosidase enzyme in vitro in concentration-dependent manner and the inhibition rate was 16.6%-86%. ②Oral starch tolerance experiment indicated that WX-JT could decrease the postprandial blood glucose in mice at 30 min and 60 min after oral administration

which revealed that 90.48

180.96 mg·kg-1 WX-JT could inhibit the activity of α-glucosidase enzyme in vivo. ③At 3 and 9 weeks after treatment with 180.96

361.92 mg·kg-1 WX-JT

the fasting blood glucose

non-fasting blood glucose and the level of HbA1c in KK-Aymice decreased remarkably in dose-dependent manner. Oral glucose tolerance test revealed that WX-JT could improve the glucose tolerance of KK-Ay mice. Conclusion: Both in vivo and in vitro experiment indicate that WX-JT can inhibit the activity of α-glucosidase enzyme. After a long-term administration with WX-JT

the indexes associated with blood glucose in type 2 diabetic KK-Ay mice decreased significantly

which indicates that WX-JT can decrease blood glucose by inhibiting the activity of α-glucosidase enzyme.